Disc Medicine Aligns with FDA on Bitopertin Approval Pathway
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Source: Newsfilter
- FDA Meeting Outcome: Disc Medicine completed a Type A meeting with the FDA, confirming that a successful Phase 3 APOLLO study could serve as the basis for a Complete Response Letter (CRL) for Bitopertin, indicating the company's potential in treating erythropoietic protoporphyria (EPP).
- Clinical Trial Progress: The APOLLO study is a double-blind, placebo-controlled Phase 3 trial involving patients aged 12 and above with EPP and X-linked protoporphyria, focusing on average monthly sunlight exposure without pain and changes in blood metal-free PPIX over six months, with data expected in Q4 2026.
- Future Plans: Disc aims to submit the CRL response by the end of 2026, with an FDA decision anticipated by mid-2027, providing investors with a clear timeline that could influence stock price and market confidence.
- Potential of Bitopertin: As an oral GlyT1 inhibitor designed to modulate heme biosynthesis, Bitopertin is positioned to be the first disease-modifying therapy for erythropoietic diseases, showcasing Disc's innovative potential in the hematologic treatment landscape.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IRON?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IRON
Wall Street analysts forecast IRON stock price to rise
13 Analyst Rating
13 Buy
0 Hold
0 Sell
Strong Buy
Current: 67.250
Low
100.00
Averages
120.20
High
154.00
Current: 67.250
Low
100.00
Averages
120.20
High
154.00
About IRON
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps), including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. It is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Disc Medicine Aligns with FDA on Bitopertin Approval Pathway
- FDA Meeting Outcome: Disc Medicine completed a Type A meeting with the FDA, confirming that a successful Phase 3 APOLLO study could serve as the basis for a Complete Response Letter (CRL) for Bitopertin, indicating the company's potential in treating erythropoietic protoporphyria (EPP).
- Clinical Trial Progress: The APOLLO study is a double-blind, placebo-controlled Phase 3 trial involving patients aged 12 and above with EPP and X-linked protoporphyria, focusing on average monthly sunlight exposure without pain and changes in blood metal-free PPIX over six months, with data expected in Q4 2026.
- Future Plans: Disc aims to submit the CRL response by the end of 2026, with an FDA decision anticipated by mid-2027, providing investors with a clear timeline that could influence stock price and market confidence.
- Potential of Bitopertin: As an oral GlyT1 inhibitor designed to modulate heme biosynthesis, Bitopertin is positioned to be the first disease-modifying therapy for erythropoietic diseases, showcasing Disc's innovative potential in the hematologic treatment landscape.
See More
Disc Medicine Faces Securities Claims Investigation
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Disc Medicine (NASDAQ: IRON) for possibly issuing misleading business information, indicating significant legal risks that could impact the company's market reputation.
- FDA Rejection of NDA: On February 13, 2026, the FDA issued a Complete Response Letter rejecting Disc Medicine's new drug application due to uncertainties requiring additional evidence, which caused the stock price to plummet by 22% on the same day, directly undermining investor confidence.
- Class Action Preparation: Rosen Law Firm is preparing a class action lawsuit against Disc Medicine, allowing investors to seek compensation without upfront costs, suggesting the company may face substantial liability that could exacerbate its financial pressures.
- Law Firm's Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling such cases effectively.
See More
Disc Medicine Aligns with FDA on Bitopertin Regulatory Path
- FDA Meeting Outcome: Disc Medicine has completed a Type A meeting with the U.S. FDA regarding the NDA for bitopertin, confirming that the ongoing Phase 3 APOLLO study, if successful, can serve as the basis for a CRL response, paving the way for traditional approval.
- APOLLO Study Design: This double-blind, placebo-controlled Phase 3 trial enrolls patients aged 12 and older with EPP and XLP, primarily assessing average monthly time in sunlight without pain during the last month of the six-month treatment period and the percent change in whole blood metal-free protoporphyrin IX after six months.
- Data Expectations and Timeline: Data from the APOLLO study is expected in Q4 2026, with a CRL response submission planned by year-end and an FDA decision anticipated by mid-2027, which will significantly impact the market prospects for bitopertin.
- Market Performance and Strategic Commitment: Disc Medicine's stock has traded between $40.00 and $99.50 over the past year, currently priced at $67.49, up 2.56%, with the CEO emphasizing the commitment to advancing bitopertin as a potential first disease-modifying therapy for EPP patients.
See More
Disc Medicine Reaches Consensus with FDA on Bitopertin Approval Path
- FDA Consensus Achieved: Disc Medicine announced a consensus with the FDA, paving the way for U.S. approval of its rare disease therapy bitopertin, indicating potential regulatory recognition that could boost the company's stock price.
- Clinical Trial Progress: The FDA highlighted the possibility of traditional approval for bitopertin during a recent meeting, contingent on positive results from the ongoing Phase 3 trial, which enhances the drug's market outlook.
- International Trial Plan: The international trial, named APOLLO, will target patients aged 12 and older with EPP and X-linked protoporphyria, with data expected in Q4 2026, laying the groundwork for FDA approval if results are favorable.
- Future Plans: Disc Medicine plans to submit a response to the CRL seeking potential FDA approval for bitopertin by mid-2027 after obtaining trial data, demonstrating the company's proactive approach to future market opportunities.
See More
Rosen Law Firm Investigates Securities Claims for Disc Medicine Shareholders
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ:IRON) for allegedly issuing misleading business information, indicating significant legal risks for the company.
- FDA Response Impact: On February 13, 2026, the FDA issued a Complete Response Letter to Disc Medicine, rejecting its new drug application and causing a 22% drop in stock price on the same day, reflecting market pessimism about the company's future.
- Class Action Preparation: The Rosen Law Firm is preparing a class action to seek compensation for investor losses, emphasizing that investors can participate without any out-of-pocket costs, showcasing the accessibility of legal support.
- Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and experience in handling similar cases.
See More
Disc Medicine Faces Securities Claims Investigation
- Securities Claims Investigation: Rosen Law Firm is investigating Disc Medicine (NASDAQ: IRON) for potentially issuing materially misleading business information, which may expose shareholders to securities claims.
- Stock Price Plunge: On February 13, 2026, Disc Medicine's stock fell 22% following the FDA's Complete Response Letter regarding its bitopertin program, indicating significant market concerns about the company's future prospects.
- Class Action Preparation: The firm is preparing a class action to recover investor losses, allowing investors to participate without any out-of-pocket fees, demonstrating a strong commitment to protecting investor rights.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, highlighting its robust capabilities and successful track record in the securities litigation space.
See More
Disc Medicine Aligns with FDA on Bitopertin Approval Pathway
- FDA Meeting Outcome: Disc Medicine completed a Type A meeting with the FDA, confirming that a successful Phase 3 APOLLO study could serve as the basis for a Complete Response Letter (CRL) for Bitopertin, indicating the company's potential in treating erythropoietic protoporphyria (EPP).
- Clinical Trial Progress: The APOLLO study is a double-blind, placebo-controlled Phase 3 trial involving patients aged 12 and above with EPP and X-linked protoporphyria, focusing on average monthly sunlight exposure without pain and changes in blood metal-free PPIX over six months, with data expected in Q4 2026.
- Future Plans: Disc aims to submit the CRL response by the end of 2026, with an FDA decision anticipated by mid-2027, providing investors with a clear timeline that could influence stock price and market confidence.
- Potential of Bitopertin: As an oral GlyT1 inhibitor designed to modulate heme biosynthesis, Bitopertin is positioned to be the first disease-modifying therapy for erythropoietic diseases, showcasing Disc's innovative potential in the hematologic treatment landscape.
See More
Disc Medicine Faces Securities Claims Investigation
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Disc Medicine (NASDAQ: IRON) for possibly issuing misleading business information, indicating significant legal risks that could impact the company's market reputation.
- FDA Rejection of NDA: On February 13, 2026, the FDA issued a Complete Response Letter rejecting Disc Medicine's new drug application due to uncertainties requiring additional evidence, which caused the stock price to plummet by 22% on the same day, directly undermining investor confidence.
- Class Action Preparation: Rosen Law Firm is preparing a class action lawsuit against Disc Medicine, allowing investors to seek compensation without upfront costs, suggesting the company may face substantial liability that could exacerbate its financial pressures.
- Law Firm's Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling such cases effectively.
See More
Disc Medicine Aligns with FDA on Bitopertin Regulatory Path
- FDA Meeting Outcome: Disc Medicine has completed a Type A meeting with the U.S. FDA regarding the NDA for bitopertin, confirming that the ongoing Phase 3 APOLLO study, if successful, can serve as the basis for a CRL response, paving the way for traditional approval.
- APOLLO Study Design: This double-blind, placebo-controlled Phase 3 trial enrolls patients aged 12 and older with EPP and XLP, primarily assessing average monthly time in sunlight without pain during the last month of the six-month treatment period and the percent change in whole blood metal-free protoporphyrin IX after six months.
- Data Expectations and Timeline: Data from the APOLLO study is expected in Q4 2026, with a CRL response submission planned by year-end and an FDA decision anticipated by mid-2027, which will significantly impact the market prospects for bitopertin.
- Market Performance and Strategic Commitment: Disc Medicine's stock has traded between $40.00 and $99.50 over the past year, currently priced at $67.49, up 2.56%, with the CEO emphasizing the commitment to advancing bitopertin as a potential first disease-modifying therapy for EPP patients.
See More
Disc Medicine Reaches Consensus with FDA on Bitopertin Approval Path
- FDA Consensus Achieved: Disc Medicine announced a consensus with the FDA, paving the way for U.S. approval of its rare disease therapy bitopertin, indicating potential regulatory recognition that could boost the company's stock price.
- Clinical Trial Progress: The FDA highlighted the possibility of traditional approval for bitopertin during a recent meeting, contingent on positive results from the ongoing Phase 3 trial, which enhances the drug's market outlook.
- International Trial Plan: The international trial, named APOLLO, will target patients aged 12 and older with EPP and X-linked protoporphyria, with data expected in Q4 2026, laying the groundwork for FDA approval if results are favorable.
- Future Plans: Disc Medicine plans to submit a response to the CRL seeking potential FDA approval for bitopertin by mid-2027 after obtaining trial data, demonstrating the company's proactive approach to future market opportunities.
See More
Rosen Law Firm Investigates Securities Claims for Disc Medicine Shareholders
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ:IRON) for allegedly issuing misleading business information, indicating significant legal risks for the company.
- FDA Response Impact: On February 13, 2026, the FDA issued a Complete Response Letter to Disc Medicine, rejecting its new drug application and causing a 22% drop in stock price on the same day, reflecting market pessimism about the company's future.
- Class Action Preparation: The Rosen Law Firm is preparing a class action to seek compensation for investor losses, emphasizing that investors can participate without any out-of-pocket costs, showcasing the accessibility of legal support.
- Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and experience in handling similar cases.
See More
Disc Medicine Faces Securities Claims Investigation
- Securities Claims Investigation: Rosen Law Firm is investigating Disc Medicine (NASDAQ: IRON) for potentially issuing materially misleading business information, which may expose shareholders to securities claims.
- Stock Price Plunge: On February 13, 2026, Disc Medicine's stock fell 22% following the FDA's Complete Response Letter regarding its bitopertin program, indicating significant market concerns about the company's future prospects.
- Class Action Preparation: The firm is preparing a class action to recover investor losses, allowing investors to participate without any out-of-pocket fees, demonstrating a strong commitment to protecting investor rights.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, highlighting its robust capabilities and successful track record in the securities litigation space.
See More
